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Abstract 
 
The selective α2-adrenoreceptor agonist, dexmedetomidine has shown 
neuroprotective, analgesic, anti-inflammatory and sympatholytic properties that may 
be beneficial in neonatal encephalopathy (NE). As therapeutic hypothermia is only 
partially effective, adjunct therapies are needed to optimize outcomes. The aim was 
to assess whether hypothermia+dexmedetomidine augments neuroprotection 
compared to routine treatment (hypothermia+fentanyl sedation) in a piglet model of 
NE using magnetic resonance spectroscopy (MRS) biomarkers, which predict 
outcome in babies with NE, and immunohistochemistry. After hypoxia-ischaemia 
(HI), 20 Large White male piglets were randomized to: (i) Hypothermia+fentanyl with 
cooling to 33.5°C from 2-26h; or (ii) Hypothermia+dexmedetomidine (loading dose 
2μg/kg at 10 minutes followed by 0.028μg/kg/h for 48h). Whole-brain phosphorus-31 
and regional proton MRS were acquired at baseline, 24 and 48 h after HI. At 48 h, 
cell death (TUNEL) was evaluated over 7 brain regions.  Between 2-3.5h there was a 
lower heart rate (p<0.03) followed by an increased heart rate (p<0.001) from 3.5-26h, 
a lower mean blood pressure 3.5-48h (p<0.001), a higher lactate from 3.5-26h 
(p<0.05) and more cardiac arrests (p<0.05). Hemodynamic effects occurred despite 
dexmedetomidine plasma levels within the target sedative range of 1 μg/L. Thalamic 
and white matter Lactate/N Acetyl aspartate did not differ between groups (p=0.66 
and 0.21 respectively); whole brain NTP/epp was similar (p=0.73) over 48h. TUNEL 
positive cell death was higher in the hypothermia+dexmedetomidine compared to the 
hypothermia+fentanyl group (mean count 5.1 versus 2.3, difference 2.8 (95% C.I. 0.6 
to 4.9), p=0.036). Hypothermia+dexmedetomidine was associated with adverse 
cardiovascular events even within the recommended clinical sedative plasma level 
and was neurotoxic following HI in our piglet NE model. These pre-clinical safety and 
efficacy data suggest dexmedetomidine should not be used with cooling following 
NE.  
 
 
 
 
 
 
 
 
 
 Introduction 
Intrapartum-related neonatal encephalopathy (NE) leads to a significant global public 
health burden resulting in 50 million disability life adjusted years in babies who 
survive; in 2010 this related to 2.4% of the Global Burden of Disease and 6.1 million 
years of life with disability [1, 2]. In developed countries therapeutic hypothermia 
reduces the combined rate of mortality and severe disability in moderate to severe 
HIE with number needed to treat of 6-7 [3]. However despite cooling, around 50% of 
infants have adverse outcomes [4]. Effective and safe adjunct therapies are needed 
to augment hypothermic neuroprotection. 
 
Dexmedetomidine is a highly selective 2-adrenoceptor agonist that confers 
sedative, anti-inflammatory, analgesic, sympatholytic and organ-protective properties 
[5]. Pre-clinical [6] and clinical studies [7] show the importance of sedation during 
therapeutic hypothermia and recent data has shown the critical importance of the 
sensitizing effect of perinatal inflammation and infection in both high and low-income 
socio-economic groups [8-10]. There are concerns with the routine long term use of 
opiates in neonates [11]. A sedative that enhances macrophage phagocytosis and 
bacterial clearance, minimizing inflammation-induced brain injury with no 
neurotoxicity would be particularly helpful in these patients.  
 
Dexmedetomidine has extensive experimental support for its neuroprotective effects 
by both 2 and non-2 adrenoceptor mediated mechanisms. Dexmedetomidine has 
shown neuroprotection in neonatal models of hypoxic-ischaemic brain injury [12, 13] 
and anesthetic brain injury in rodents. Dexmedetomidine has a dose dependent anti-
inflammatory effect on plasma cytokine release following sepsis [14, 15] and 
neuroprotective properties in sepsis-induced brain injury [16].  
 
Dexmedetomidine has been used as a sedative in critically ill children and neonates 
[17]. A dose dependent hemodynamic response has been seen with hypotension, 
hypertension and bradycardia particularly with increasing plasma concentrations [18-
20]. Dexmedetomidine effects may be opposing and depend on central and 
peripheral actions. Close monitoring of circulatory dynamics with dexmedetomidine 
has been recommended especially with therapeutic hypothermia where there is 
potential for altered pharmacokinetics (PK) and pharmacodynamics [21]. In our 
previous study, we investigated dexmedetomidine PK during hypothermia and 
rewarming to determine the safe and effective dose for use in a study of 
neuroprotection after hypoxia-ischaemia. We found a significantly reduced 
dexmedetomidine clearance due to cumulative effects of hypothermia and hypoxia-
ischaemia. Indeed, dexmedetomidine clearance was reduced almost ten fold 
compared to adult values; PK analysis estimated a loading dose of 2 μg/kg 
dexmedetomidine followed by 0.028 μg/kg/h would achieve the sedative target 
plasma concentration of 0.5–0.6 μg/l with hypothermia after hypoxia-ischaemia  [22]. 
 
We hypothesized that hypothermia+dexmedetomidine would lead to better brain 
protection than hypothermia+fentanyl after global hypoxia ischemia. Our aim was to 
assess whether an optimized dose of dexmedetomidine started 10 minutes after 
hypoxia ischemia augments routine hypothermic neuroprotection in a piglet perinatal 
asphyxia model. This model also has strong similarities to newborn infants with NE in 
terms of the timing of the evolution of injury after hypoxia ischemia [23, 24], pattern of 
injury, neuropathology and cerebral magnetic resonance spectroscopy (MRS) [25]. 
The efficacy of dexmedetomidine protection was assessed using: (i) Cerebral MRS 
biomarkers, proton (1H) MRS lactate/ N acetyl aspartate (NAA) [25] and phosphorus-
31 (31P) MRS for phosphocreatine/inorganic phosphate (PCr/Pi) and NTP/ 
exchangeable phosphate pool (epp) [23]; and (ii) Histological assessment of cell 
death using TUNEL at 48 h after hypoxia ischemia. 
 Material and Methods 
Sample size calculation 
Our primary outcomes were cerebral lactate/NAA and NTP/epp. Previous work with 
our model suggested that the change in lactate/NAA during 48 h varied between 
normo- and hypothermic groups by 1.0 U, with a standard deviation of 0.65 U (log 
scale). Assuming similar magnitude of additional effect for 
hypothermia+dexmedetomidine following hypoxia ischemia versus 
hypothermia+fentamyl and similar variability at 48 h and with 5% significance and 
80% power, at least eight subjects were required in each group based on a two-
sample t-test sample size calculation. 
 
Animal experiments and surgical preparation 
All animal experiments were approved by the ethics committee of UCL and 
performed under UK Home Office Guidelines [Animals (Scientific procedures) Act, 
1986]. The study complies with the ARRIVE guidelines. Twenty newborn male piglets 
with a birth weight of 1.6-2.1kg <48 h of age were anaesthetized and surgically 
prepared as described previously [24].  The study timeline is shown in Figure 1.  
 
Following clinical assessment, piglets were sedated with intramuscular midazolam 
(0.2 mg/kg). Whilst monitoring arterial oxygen saturation (SpO2), anesthesia was 
induced by inhalation of isoflurane (4% v/v) through a facemask to facilitate 
tracheostomy and intubation. Throughout the surgery, isoflurane was maintained at 
2.8–3% guided by peripheral oxygen saturation monitoring (Nonin Medical, 
Plymouth, MN, USA) and the animal's response to stimulation. Following 
tracheostomy, a suitable size of endotracheal tube (Smiths Medical, Ashford, Kent, 
UK) was fixed and the piglet was mechanically ventilated (SLE 2000 infant 
Ventilator, Surrey, UK). Ventilator settings were adjusted to maintain partial pressure 
of oxygen (PaO2) at 8–13 kPa and carbon dioxide (PaCO2) at 4.5–6.5 kPa, allowing 
for temperature and fraction of inspired oxygen (FiO2) correction of the arterial blood 
sample. After the airway was secured, both common carotid arteries were surgically 
isolated at the level of the fourth cervical vertebra and a vascular occluder (OC2A, In 
Vivo Metric, Healdsburg, CA, USA) was placed on each side. After completion of 
surgery, inspired isoflurane concentration was maintained at 2% v/v. 
 
An umbilical venous catheter was inserted for infusion of maintenance fluids (10% 
dextrose, 60 ml/kg/day before the insult and 40 ml/ kg/day after resuscitation), 
fentanyl (5 μg/kg/h in the cooling group, and antibiotics (benzyl penicillin 50mg/kg, 
every 12 h and gentamicin 4mg/kg, once a day). An umbilical arterial catheter was 
inserted for invasive physiologic monitoring (SA instruments) for heart rate and 
arterial blood pressure, and blood sampling for arterial gases and electrolytes (Abbot 
Laboratories, UK). Hepsal (0.5 IU/ml of heparin in 0.9% saline solution) was infused 
at rate of 0.3 ml/h to prevent umbilical arterial catheter blockage. 
 
Piglets were cared for under intensive care conditions throughout the experiment. To 
maintain the MABP above 40mm Hg, bolus infusions of 0.9% saline (Baxter; 10 
ml/kg), dopamine (5–20 μg/kg/min), dobutamine (5–20 μg/kg/min) and adrenaline 
(0.1–1.5 μg/kg/min) were used as required by a NICU trained clinician. High serum 
lactate was treated by optimizing oxygenation and 0.9% saline bolus infusions. 
Hyperkalemia (K>7.0 mmol/l) was treated with 4 μg/kg salbutamol (10 μg/ml) over 10 
min. 
 
MR methods 
The head was immobilized in a stereotactic frame for MRS acquisition. Piglets were 
positioned within the bore of 9.4 TESLA AGILENT MR scanners. 1H and 31P MRS 
data were acquired at baseline and at 24 and 48 h after cerebral hypoxic ischemia. 
 
31P MRS 
A 7 cm x 5 cm elliptical transmit-receive MRS surface coil tuned to the 31P resonant 
frequency was positioned on top of the head. 31P MRS was acquired with 1-minute 
resolution using a non-localized single-pulse acquisition. MRS data were analyzed 
using the Advanced Method for Accurate, Robust and Efficient Spectral fitting of 
MRS data with use of prior knowledge (AMARES)[26] as implemented in the jMRUI 
software. Prior knowledge of NTP multiplet structure was used. NTP is predominately 
ATP and the latter contributes approximately 70% of the NTP signal [27]. Thus NTP 
changes during this experiment predominately reflected ATP changes. Pi was fitted 
using 4 separate components and PCr with a single component. The following peak-
area ratios were calculated: Pi/epp, PCr/epp, and NTP/epp where epp = 
exchangeable phosphate pool= Pi + PCr + 2γ-NTP + β-NTP. 
 
1HMRS 
1H MRS data were collected from voxels located in the dorsal right subcortical white 
matter at the centrum semiovale level (white matter voxel, 8 Å~ 8 Å~ 15mm) and in 
the deep gray matter centered on both lateral thalami (deep gray matter voxel, 15 Å~ 
15 Å~ 10mm) using a combination of a 65 Å~55mmelliptical receive surface coil, a 
150mm diameter transmit volume coil and a LASER acquisition (TR = 5000 ms, TE = 
288 ms, 128 averages). Spectra were analyzed using AMARES as implemented 
in the jMRUI software and the lactate/NAA peak area ratio was calculated. 
 
Cerebral hypoxiaischemia  
31P MRS data were collected at baseline, during hypoxia ischemia and for one hour 
after cessation of hypoxia ischemia. Hypoxia ischemia was induced inside the MR 
scanner by remotely inflating the vascular occluders around both common-carotid 
arteries, and simultaneously reducing FiO2 to 6% (vol/vol). During hypoxia ischemia 
the β-NTP peak height was continuously monitored using in-house Matlab 
(Mathworks) software. At the point at which β-NTP had fallen to 50% of its baseline 
value, FiO2 was increased to 9%. When β-NTP fell to 40% baseline height the 
inspired oxygen fraction was titrated to keep the β-NTP peak height between 30% 
and 40% of its original height for a period of 12.5 min. At the end of hypoxia ischemia 
the carotid arteries were de-occluded and the FiO2 returned to 21%. 
 
Experimental groups 
Following transient hypoxia ischemia and after resuscitation, piglets were 
randomized to: (i) Hypothermia+fentanyl throughout the study n=10 or (ii) 
hypothermia+dexmedetomidine n=10.  A loading dose of 2 μg/kg dexmedetomidine 
was started at 10 minutes after resuscitation and infused over 20 minutes followed by 
a maintenance dose at 0.028 μg/kg/h for the next 48 h. Fentanyl was stopped upon 
starting maintenance dexmedetomidine. Blood for dexmedetomidine PK assay was 
sampled at 10, 20, 40 and 60 minutes and thereafter at 2, 4, 6, 12, 24, 36 and 48 
hours after HI. Both groups were cared for over 48 h after hypoxia ischemia and 
maintained hypothermic (core temperature 33.5 °C) between 2–26 h. Physiological 
parameters were compared between groups with Mann–Whitney at each time point. 
 
Amplitude integrated EEG (aEEG) 
After surgical preparation, multichannel six-lead EEG monitoring (Nicolet Care 
Fusion, Wisconsin, USA) was recorded at baseline and throughout the periods 
between MRS data acquisitions. Filtered amplitude integrated EEG (aEEG) 
recordings were classified according to the voltage criteria [28]. Grade 1 was 
severely abnormal voltage with lower and upper margin of the bandwidth <5µV and 
<10 µV respectively, grade 2 lower margin and upper margin <5 µV and >10 µV 
respectively and grade 3 lower and upper margin >5 µV and >10 µV respectively. 
  
Brain histology 
At 48 h after hypoxia ischemia, piglets were euthanized with pentobarbital, 
the brain was fixed by cardiac perfusion with cold 4% paraformaldehyde, 
dissected out and post-fixed at 4 °C in 2% paraformaldehyde for 7 days. Coronal 
slices (5 mm thick) of the right hemisphere, starting from anterior to the optic 
chiasma, were embedded in paraffin, sectioned to 8-μmthickness and stained with 
hematoxylin and eosin to validate the bregma for analysis. For each animal, 2 
sections (bregma 00 and −2.0) were stained and 7 different regions in the brain were 
examined (Figure 2). 
 
To assess cell death, brain sections were stained for nuclear DNA fragmentation 
using histochemistry with transferase mediated biotinylated d-UTP nick end-labeling 
(TUNEL) as previously described [29]. Briefly, TUNEL sections were pretreated in 
3% hydrogen peroxide, subjected to a protease K pre-digestion (Promega, 
Southampton, UK) and incubated with TUNEL solution (Roche, Burgess Hill, UK). 
TUNEL was visualized using avidin-biotinylated horseradish complex (ABC, Vector 
Laboratories, Peterborough, UK) and diaminobenzidine/ H2O2 (DAB, Sigma, Poole, 
UK) enhanced with CoSO4 and NiCl2. TUNEL sections were dehydrated and cover-
slipped with DPX (VWR, Leighton Buzzard, UK). For each animal and brain region, 
TUNEL-positive nuclei were counted at two levels and from 7 regions by an 
investigator blind to the treatment group and the average converted into counts per 
mm2. 
 
Statistical Methods 
Physiological variables 
Mean (SD) values of baseline variables and variables throughout the study at time 0 
(end of insult), 2-3.5h after time 0, 3.5-26h after time 0 and 26-48h after time 0 were 
grouped and compared between groups using the Mann Whitney test. 
 
MRS 
All analyses were performed using the SAS JMP® v11.0.0 software. A statistical 
model was fitted to the ratios NTP/epp, PCr/Pi and Lac/NAA. An analysis of variance 
(ANOVA) model was fitted and the differences in the means on the log scale for the 
two treatment groups (Hypothermia+dexmedetomidine versus 
Hypothermia+fentanyl) were estimated from the model at each of the three time 
points with 95% confidence intervals (CIs) for the differences. The differences in 
treatment group means are shown graphically using 95% Least Significant Difference 
error bars.  
 
aEEG 
Following the baseline scoring, scores were assigned at 3, 6, 12, 24 and 36h after 
hypoxia ischaemia and group averages compared.  
 
TUNEL 
An analysis of variance model was fitted to the mean counts to give an estimate of 
the expected counts per mm2. The overall difference between the means for the two 
treatment groups, and treatment differences across regions are presented with 95% 
C.I.s and graphically using 95% Least Significant Difference error bars. 
 
Pharmacokinetics 
A one compartment linear disposition model was used to fit data to the PK model. 
Population parameter estimates were obtained using non-linear mixed effects 
modelling (NONMEM VII, Globomax LLC, Hanover, MD, USA) [30]. This model 
accounts for population parameter variability (between subjects) and residual 
variability (random effects) as well as parameter differences predicted by covariates 
(fixedeffects). A visual predictive check (VPC) [31], a modelling tool that estimates 
the concentration prediction intervals and graphically superimposes these intervals 
on observed concentrations after a standardised dose, was used to evaluate how 
well the model predicted the distribution of observed dexmedetomidine 
concentrations. Simulation was performed using 1000 subjects with characteristics 
taken from 10 studied piglets; these simulations were generated by randomly using 
values from the estimated parameters and their variability. This is an advanced 
internal method of evaluation [32, 33] and is considered better than the commonly 
used plots of observed vs. predicted values [34]. For data such as these where 
covariates such as weight are different for each piglet, we used a prediction 
corrected VPC (PC-VPC) [35]. Observations and simulations are multiplied by the 
population baseline value divided by the individual-estimated baseline. 
 
 
 
 
 
 
Results 
There were 10 animals in each group.   
Baseline Physiological Data and Insult severity  
There were no intergroup differences in bodyweight, postnatal age, baseline 
physiological (heart rate and mean arterial blood pressure) measures and the HI 
severity and duration between groups as shown in Table 1. The baseline oxygen 
was higher in the dexmedetomidine and cooling group but similar for other time 
epochs.  
 
Heart rate and blood pressure throughout the study 
The heart rate in the hypothermia+dexmedetomidine group was lower between 2-
3.5h after the start of dexmedetomidine (p=0.03). Between 3.5 and 26 h, the heart 
rate was higher in the dexmedetomidine and cooling group (p<0.001). The mean 
blood pressure remained lower in the hypothermia+dexmedetomidine group from 
3.5h to the end of the study (p<0.001). The rectal temperature was transiently lower 
in the hypothermia+dexmedetomidine group compared to the hypothermia+fentanyl 
group between 2-3.5h (p=0.03). Blood lactate was higher in the 
hypothermia+dexmedetomidine group 3.5-26h after time 0 (p=0.02).  
 
The fluid and inotrope requirement comparison between groups is shown in Table 2. 
There were trends to increased geloplasma infusion volume (p=0.06), noradrenaline 
(p=0.07) and total adrenaline (p=0.07) requirements in the 
hypothermia+dexmedetomidine group compared to the hypothermia+fentanyl group. 
There were three fatal cardiac arrests in the hypothermia+ dexmedetomidine group 
(two at 36h and one at 45h after hypoxia ischemia) and none in the hypothermia plus 
fentanyl group.  
 
MRS analysis 
The least squares means plots and 95% Least Significant Difference (LSD) bars for 
NTP/epp, PCr/Pi and Lac/NAA (on log 10 scale) in thalamus and white matter are 
shown in Figure 3. The differences in the means and CI at 48h are shown in Table 
3. There was no difference at 48h between groups for any of the MRS peak area 
ratios. At 24h, the hypothermia+dexmedetomidine group brain NTP/epp was lower 
than hypothermia+fentanyl (p=0.05), but at 48h this difference was not observed.  
 
EEG 
There was no difference between the group mean aEEG scores at any time point for 
the hypothermia + fentanyl compared to the hypothermia + dexmedetomidine groups 
(Figure 4). 
 
Hypothermia+ dexmedetomidine increased TUNEL positive cell counts 
Representative photomicrographs of TUNEL staining in the putamen and 
periventricular are shown in Figure 5A. A paired t-test comparing the overall TUNEL 
count means (across all fields and subjects) of the two treatment groups for each of 
the 7 regions and overall was performed (Table 4).  There was evidence of a 
difference between treatment groups (p=0.036) (Figure 5B) with 
hypothermia+dexmedetomidine with more TUNEL positive cells than 
hypothermia+fentanyl.  The overall mean count for the 
hypothermia+dexmedetomidine group was 5.1 compared with a mean count of 2.3 
for the hypothermia+fentanyl; a mean difference of 2.8 (95% CI 0.6-4.9). The 
regional brain counts for the two groups are shown in Figure 5C.  
 
Dexmedetomidine PK  
The mean plasma concentrations of dexmedetomidine following a loading dose of 2 
μg/kg over 20 minutes followed by an infusion of 0.028 μg/kg/h were below 1 μg/L, 
despite the model predicting slightly higher concentrations (Figure 6). Figure 6A 
shows prediction corrected observed concentrations. Figure 6B shows prediction 
corrected percentiles (10%, 50%, 90%) for observations (red lines with symbols) and 
predictions (lines) with 95% confidence intervals for prediction percentiles (grey 
shaded areas). The dexmedetomidine plasma levels (observations) were as 
predicted and mainly within the clinical sedative range of <1 μg/L.  
 Discussion 
Compared to routine hypothermia+ fentanyl sedation after hypoxia-ischaemia, we did 
not observe any improvement in cerebral protection based on magnetic resonance 
biomarkers lactate/NAA and NTP/epp with hypothermia+dexmedetomidine. There 
was increased cell death across the combined 7 brain regions with hypothermia+ 
dexmedetomidine compared to hypothermia+fentanyl. There was evidence of the 
haemodynamic effects of dexmedetomidine with a lower heart rate between 2-3.5h 
followed by an increased heart rate, a lower mean blood pressure and a higher 
lactate from 3.5-26h. There were more fatal cardiac arrests in the 
hypothermia+dexmedetomidine group. The hemodynamic effects occurred despite 
dexmedetomidine plasma levels within target sedative range of 1 μg/L.  
 
In preparation for this efficacy study, we previously studied the pharmacokinetics of 
dexmedetomidine in the piglet [36]; compared with adult values, clearance was 
reduced almost tenfold in the newborn piglet following hypoxic ischemic brain injury 
and subsequent therapeutic hypothermia. This reduced clearance was related to 
cumulative effects of both hypothermia and exposure to hypoxia. We observed that 
high plasma levels of dexmedetomidine were associated with major cardiovascular 
complications and were able to estimate from a one compartment model, that a bolus 
of 2 μg/kg dexmedetomidine over 20 min followed by an infusion of 0.028 μg/kg/h 
dexmedetomidine during therapeutic hypothermia would likely achieve a plasma 
concentration of 0.5–0.6 μg/l (concentration associated with sedation in human 
newborns). In the current study, despite achieving plasma levels mainly < 1 μg/L with 
the calculated infusion rate, we saw adverse cardiovascular responses; there was no 
relation between the plasma concentration and adverse cardiovascular responses.  
 
Many of the properties of dexmedetomidine, including sedation are transduced via 
2-adrenoceptor signaling. 2 receptors are located in blood vessels, sympathetic 
terminals and the brain, where their activation causes vasoconstriction, anxiolysis, 
sedation and analgesia. Dexmedetomidine is 1600 times more specific to α2 than α1 
receptors, permitting its use for sedation without cardiovascular side effects of α1 
receptor activation [19, 37]. Dexmedetomidine stands out from other sedatives 
including opioids for its minimal respiratory depression, anti shivering effect and 
prevention of opioid induced muscle rigidity [38]. The variable hemodynamic changes 
we saw in our study can be explained by the properties of dexmedetomidine in that 
there are opposing effects on the cardiovascular system: in the central nervous 
system dexmedetomidine produces sympatholysis and a reduction in blood pressure, 
in the peripheral nervous system it causes vasoconstriction leading to an increase in 
blood pressure.  
A recent phase II/III multicenter, safety and pharmacokinetic study of 
dexmedetomidine in term and preterm infants (>28-<44 weeks gestation) suggested 
that dexmedetomidine is effective for sedating preterm and full-term neonates and is 
well-tolerated without significant adverse events [39]. There were three adverse 
events observed (hypo and hypertension and agitation). The PK profile of 
dexmedetomidine was different in neonates compared with older children with a 
longer half-life and larger area under the curve drug concentration over time; this 
confirms our previous findings in the piglet indicating that lower doses are required to 
achieve the same levels of sedation and avoid adverse effects with newborns. In 
other clinical studies, bradycardia, hypotension and hypertension have been 
observed in children to varying degrees depending on the plasma concentration of 
dexmedetomidine [40-42]. In our study the combination of immaturity, hypoxia 
ischemia and hypothermia are likely to have increased the risk of adverse effects 
from dexmedetomidine despite plasma levels mainly < 1 μg/L. 
There are counteracting and complex interactions between α2- agonist and α2- 
adrenoreceptor subtypes which may be affected by hypothermia. Alpha2-Adrenergic 
receptors present in the brainstem decrease blood pressure; activation of 
presynaptic α2A- adrenoreceptors decreases sympathetic outflow and norepinephrine 
release causing hypotension and bradycardia [43-45]. Postsynaptic α2B- 
adrenoreceptors on vascular smooth muscle mediate vasoconstriction and are 
responsible for hypertension. Presynaptic α2C- adrenoreceptors are also inhibitory 
autoreceptors with a prominent role in peripheral autonomic system [46]; these 
receptors are sensitive to temperature and become active at temperatures below 
37°C [47-49].  All piglets in our study were cooled from 2-26 hours after hypoxia 
ischemia and the adverse cardiovascular effects (bradycardia and hypotension) may 
be due to the combination of hypothermia+dexmedetomidine. Cooling has the 
potential to change the expression of α2C- receptors; silent intracellular α2C- receptors 
become active and translocate to the cell surface causing vasoconstriction following 
exposure to temperatures below 37°C [47, 48]. Therapeutic hypothermia related 
bradycardia has been reported in young children following dexmedetomidine infusion 
[50] [51]. Furthermore, it is known that dexmedetomidine interferes with 
thermoregulation and promotes hypothermia itself [52, 53]. This may explain our 
observation of a slightly lower body temperature between 2-3.5h in the 
hypothermia+dexmedetomdine group.  
 
It has been shown that anesthesia influences the haemodynamic effects of 
dexmedetomidine. In anesthetized patients with depressed sympathetic tone, 
dexmedetomidine increased MBP by peripheral vasoconstriction whereas in awake 
patients with intact tone, it decreased MBP via centrally mediated effect of α2 
agonists [54]. Rapid dexmedetomidine injection in a group of young children during 
isoflurane anesthesia for cardiac catheterization transiently increased systolic and 
diastolic blood pressure [55]. All piglets in our study were anesthetised with 
isoflurane throughout the experiments. Inhaled isoflurane dose dependently reduces 
cardiac output and systemic vascular resistance [56]. The negative inotropic and 
peripheral vasodilatation effects of isoflurane are likely to augment the effects of 
dexmedetomidine on cardiac output. Isoflurane anesthetised dogs and cats 
developed greater negative cardiovascular effects with dexmedetomidine as an 
adjunct compared to isoflurane only anesthesia [57, 58]. Dexmedetomidine reduces 
cardiac output and the subsequent redistribution of blood flow limits hepatic and 
other non-vital organ perfusion [59]; this in turn reduces hepatic blood flow and 
hydroxylation and clearance [60, 61].   In our piglets, it is likely that the interaction 
between dexmedetomidine (hypotension and bradycardia) and isoflurane 
anaesthesia (negative inotropic effect and vasodilation) are likely to have increased 
the depression of the sympathetic activity [62] by the variable binding to peripheral 
and  central α2 adrenergic receptors. [63].  
 
There are conflicting reports of neuroprotection and neurotoxicity with 
dexmedetomidine and clonidine. Previous pre-clinical rodent studies have shown that 
dexmedetomidine protects the brain against focal [64, 65] and global [66-68] hypoxia 
ischemia by inducing anti-apoptotic effects [69, 70] or via α2 adrenergic and imidazole 
1 receptors [13]. In the developing mouse brain there was dose dependent 
neuroprotection with dexmedetomidine and clonidine [71]. Other studies however 
have shown that dexmedetomidine and clonidine induce cerebral hypoperfusion and 
neurotoxicity in small animal stroke models [72, 73]. Dean et al showed a complex 
dose dependent response to clonidine with low dose but not high dose being 
neuroprotective after hypoxic brain injury in preterm fetal sheep [74]. We observed 
the combination of hypothermia+dexmedetomidine to be neurotoxic with increased 
TUNEL positive cells (5.1 versus 2.3 mean counts across the brain) compared to 
hypothermia+fentanyl. One mechanism leading to this in our model could be a 
reduction in cerebral blood flow (CBF) by vasoconstriction in pial arteries and veins 
[75]. Studies in rats and dogs demonstrated dexmedetomidine dose dependently 
caused vasoconstriction in pial arteries mediated either by direct action on α2- 
adrenoreceptors [76, 77] on the small cerebral arteries distal to circle of Willis [76]. 
Other studies have shown that systemic dexmedetomidine indirectly induces cerebral 
vasoconstriction by reducing cerebral oxygen consumption [75, 78, 79].  
 
The reasons for these conflicting reports may be related to differences in species, 
models, maturity of the brain, dose and timing of the drugs and the integrity of the 
autonomic system. Different expressions of α- adrenoreceptor subtypes in cerebral 
arteries in human, monkeys and dogs can lead to different responses to 
noradrenaline, α2- agonists and antagonists [80]. An age dependent change in 
expression and binding capacity of α2- receptors in postnatal life occurs in human 
and rat brain  and this may affect the sensitivity of the newborn to dexmedetomidine . 
[81-83]. 
Our study suggests that caution is needed when considering the use of 
dexmedetomidine with hypothermia in the newborn after hypoxia ischemia. We saw 
no improvement in cerebral energetics on MRS with hypothermia+dexmedetomidine 
versus hypothermia+fentanyl. There was evidence of neurotoxocity with an increased 
number of TUNEL positive cells across the brain with hypothermia+dexmedetomidine 
compared to hypothermia+fentanyl. We saw some expected hemodynamic effects of 
dexmedetomidine such as hypotension and bradycardia; adverse effects and cardiac 
arrests may relate to interactions between reduced clearance in an immature animal, 
concomitant anesthesia exacerbating the cardiovascular effects of dexmedetomidine 
and the effects of hypothermia on the temperature sensitive α2C- receptors. Reduced 
cerebral perfusion induced by dexmedetomidine is likely to have contributed to the 
neurotoxicity.   
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